Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Exclusion Criteria

• •* Aggressive NHL such as diffuse large B-cell lymphoma (DLBCL), who have relapsed or have residual disease following treatment with curative intent; patients should have relapsed following, or not be eligible for high-dose therapy and autologous HCT; patients with chemotherapy refractory disease or marrow involvement or comorbidities precluding successful autologous HCT are eligible; patients may be treated following allogeneic HCT
• •* Patients with CD19 expressing, relapsed or refractory ALL
• •* Patients with one of the above diagnoses whose disease state does not qualify but who have prognostic indicators that suggest a high risk of progression of disease may be screened and undergo leukapheresis; enrollment for T cell therapy would require meeting the full disease state eligibility
• •Confirmation of diagnosis
• •Evidence of CD19 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen or high likelihood of CD19 expression based on disease histology
• •Karnofsky performance status \>= 60%
• •All patients of childbearing potential must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusion
• •Ability to understand and provide informed consent
• •EXCLUSIONS FOR CAR-T CELL THERAPY
• •Patients requiring ongoing daily corticosteroid therapy at a dose of \> 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
• •Active autoimmune disease requiring immunosuppressive therapy is excluded unless discussed with the Principal Investigator (PI)
• •Serum creatinine \> 2.5 mg/dL
• •Serum glutamic oxaloacetic transaminase (SGOT) \> 5 x upper limit of normal
• •Bilirubin \> 3.0 mg/dL
• •Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with a forced expiratory volume in one second (FEV1) of \< 50 % of predicted will be excluded
• •Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected) \< 40% will be excluded
• •Significant cardiovascular abnormalities as defined by any one of the following: New York Heart Association (NYHA) class III or IV congestive heart failure, clinically significant hypotension, uncontrolled symptomatic coronary artery disease, or a documented ejection fraction of \< 35%
• •Uncontrolled active infection